Journal Article

Rethinking multiple sclerosis therapy beyond clinical phenotypes

Get access
Brain, Volume 149, Issue 11, November 2026, Pages 3703–3707, https://doi.org/10.1093/brain/awag273
Published:
18 August 2026
Article history
Received:
01 June 2026
Revision received:
30 June 2026
Accepted:
08 July 2026
Published:
18 August 2026
Corrected and typeset:
21 October 2026

Extract

When biology and clinical labels no longer align, drug development risks missing meaningful therapeutic effects. Multiple sclerosis trials should move beyond phenotype-based classifications toward mechanism-based evaluation.

Multiple sclerosis (MS) is being increasingly recognized as a biological continuum rather than a set of discrete clinical phenotypes. Despite advances in diagnostic criteria and data-driven reclassification efforts, clinical trial design and regulatory frameworks continue to rely on traditional course descriptors such as relapsing–remitting, secondary progressive and primary progressive MS. Recent phase 3 trials of Bruton’s tyrosine kinase (BTK) inhibitors illustrate the limitations of this phenotype-based approach. Across relapsing and progressive populations, BTK inhibition demonstrates consistent effects on disability accumulation and neurodegeneration that are not fully explained by suppression of acute inflammatory activity. Apparent discrepancies in statistical significance between trials are compatible with a shared underlying biological effect. These findings support a mechanism-centred framework for evaluating therapies targeting progression independent of relapse activity. Aligning trial design and regulatory decision-making with contemporary understanding of MS biology may improve therapeutic development and ensure equitable access to effective treatments across the disease spectrum.

You do not currently have access to this article.
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period